A doctor told a Zuellig Pharma Medical Representative that she is using a certain product that is being marketed and distributed by Zuellig Pharma for the treatment of migraine even though migraine is not a listed indication of this product in the prescribing information. The doctor got the information that the drug is effective for migraine from her friends who are also doctors. Should the Zuellig Pharma Medical Representative report this as a PV reportable event? OYes square ONo

The answer is **Yes**.Here's why:* **Off-label use:** The doctor is using the product for a condition (migraine) that is not listed in the prescribing information. This is considered off-label use.* **Pharmacovigilance (PV) reporting:** Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. * **Potential for harm:** Even if the doctor's friends have seen positive results, off-label use can still pose risks. The product may not be adequately studied for migraine, and there could be unknown side effects or interactions.* **Ethical and legal considerations:** It's important to report off-label use to ensure patient safety and to contribute to the overall knowledge base about drug safety.**The Zuellig Pharma Medical Representative has a responsibility to report this event to ensure patient safety and to contribute to the ongoing monitoring of the product's safety profile.**